Autolus has picked up its first ... (obecabtagene autoleucel or obe-cel) for the treatment of adults with relapsed or refractory B-cell precursor ALL based on the results of the phase 2 FELIX ...

Cell therapy is a field rife with innovation, but most of the novel therapies being developed fall into one of two basic categories: autologous cell therapies, which involve removing a patient’s ...

Feb. 4, 2025 — Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells in preclinical models tested in mice.

Autolus Therapeutics (NASDAQ:AUTL) stock has reached a 52-week low, touching down at $2.20, as the biopharmaceutical company faces a challenging market environment. With a market... ByInvesting ...

10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse ... Improved Prime Editing System Makes Gene-Sized Edits in Human Cells at Therapeutic Levels June 10, 2024 ...

1 Day AUTL 5.15% DJIA -0.37% Russell 2K 0.00% Health Care/Life Sciences 0.69% ...

A small but in-depth study of allogeneic CAR T cell therapy in patients with high-risk neuroblastoma shows feasibility and potential efficacy, and mechanistic insights reveal pathways to improved ...

After hours: February 20 at 6:46:07 PM EST Loading Chart for DTIL ...

Cell biology is the discipline of biological ... Low-dose adrenoreceptor blockade treatment mitigates this PAGln-induced cellular senescence. Haspin phosphorylates histone H3 threonine 3 (H3T3 ...

After hours: February 19 at 6:43:38 PM EST Loading Chart for KYTX ...